<div id="readability-page-1"><p>Mediar Therapeutics, Inc. announced that it has received $76 million in an oversubscribed round of funding co-led by new investors Amplitude Ventures Inc. and ICG America, Inc. on January 7, 2026. The company has received $38,150,185 in it's final tranche. The transaction included participation from new investors Longwood Fund, Asahi Kasei Pharma America Corporation and Alexandria Real Estate Equities, Inc. The transaction also included participation from existing investors Bristol-Myers Squibb Company, Eli Lilly and Company, Gimv NV, Mass General Brigham Ventures, LLC, Mission BioCapital, LP, Novartis Venture Funds, Ono Venture Investment, Inc., Pfizer Venture Investments LLC, Pureos Partners AG and Sofinnova Partners SAS.</p></div>

旭化成(ADR)

輝瑞

百時美施貴寶

AMPL

<p>Mediar Therapeutics, Inc. 宣佈於 2026 年 1 月 7 日獲得了來自一組投資者的 7600 萬美元融資，該輪融資由 Amplitude Ventures Inc.和 ICG America, Inc.共同主導。此次融資輪超額認購，最後一筆融資金額為 38,150,185 美元。新投資者包括 Longwood Fund 和旭化成製藥美國公司，而現有投資者如百時美施貴寶和輝瑞也參與了此次融資</p>

Mediar Therapeutics, Inc. announced that it has received $76 million in funding from a group of investors

- Mediar Therapeutics, Inc. 收到 7600 萬美元融資，由新投資者共同牽頭。  
- 各參與方包括 Amplitude Ventures Inc. 和 ICG America, Inc.。  
- 此次交易中也有眾多現有投資者參與。

Mediar Therapeutics, Inc.宣佈已獲得來自一組投資者的 7600 萬美元融資